Literature DB >> 4084733

Generalised increase in bone resorption in carcinoma of the prostate.

G H Urwin, R C Percival, S Harris, M N Beneton, J L Williams, J A Kanis.   

Abstract

Several indirect biochemical indices of bone resorption are increased in patients with carcinoma of the prostate and skeletal metastases. We have examined histological indices of bone resorption in biopsies from affected patients. Bone-forming surfaces and active osteoblast numbers were increased in skeletal sites adjacent to tumour tissue and indices of bone resorption were significantly increased at sites adjacent to tumour. Contrary to expectation, indices of bone resorption were also increased in bone distant from skeletal metastases. These findings suggest that prostatic cancer induces generalised loss of trabecular bone which may minimise disturbances in plasma calcium homeostasis but could contribute to morbidity.

Entities:  

Mesh:

Year:  1985        PMID: 4084733     DOI: 10.1111/j.1464-410x.1985.tb07040.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  22 in total

Review 1.  Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2015-01-31       Impact factor: 3.633

2.  Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Skeletal Radiol       Date:  2004-11-16       Impact factor: 2.199

Review 3.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Skeletal effects of carcinoma of the breast and prostate.

Authors:  R C Percival
Journal:  Ann R Coll Surg Engl       Date:  1986-09       Impact factor: 1.891

5.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 6.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 7.  Molecular mechanisms of metastasis in prostate cancer.

Authors:  Noel W Clarke; Claire A Hart; Mick D Brown
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 8.  Tumor-stroma co-evolution in prostate cancer progression and metastasis.

Authors:  Sajni Josson; Yasuhiro Matsuoka; Leland W K Chung; Haiyen E Zhau; Ruoxiang Wang
Journal:  Semin Cell Dev Biol       Date:  2009-12-03       Impact factor: 7.727

9.  Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.

Authors:  I Elomaa; T Kylmälä; T Tammela; J Viitanen; J Ottelin; M Ruutu; K Jauhiainen; M Ala-Opas; L Roos; J Seppänen
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

10.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.

Authors:  David P Dearnaley; Malcolm D Mason; Mahesh K B Parmar; Karen Sanders; Matthew R Sydes
Journal:  Lancet Oncol       Date:  2009-08-10       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.